Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492393 | 0.88 | PARP1 (0.42) | PARP1GPR119HDAC1HSD11B1MAPK8 | |
| SCHEMBL12723837 | 0.85 | PARP1 (0.42) | PARP1GPR119HDAC1HSD11B1MAPK8 | |
| SCHEMBL492597 | 0.82 | PIK3CD (0.35) | IDH1 | |
| SCHEMBL492375 | 0.81 | CDK4 (0.39) | PARP1 | |
| SCHEMBL492238 | 0.81 | CDK4 (0.39) | PARP1 | |
| SCHEMBL492144 | 0.79 | SUV39H2 (0.44) | GPR119HDAC1NR1H2FAAH | |
| SCHEMBL492478 | 0.79 | GRM4 (0.31) | — | |
| SCHEMBL4530941 | 0.77 | HDAC1 (0.49) | PARP1GPR119HDAC1HSD11B1MAPK8 | |
| SCHEMBL30964844 | 0.77 | GPR119 (0.45) | PARP1GPR119HDAC1HSD11B1MAPK8 | |
| SCHEMBL492117 | 0.77 | MAP3K12 (0.35) | PARP1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273891-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| US-8106066-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| US-7932248-B2 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100137288-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | SCHUMACHER RICHARD | 2010-06-03 | — | — | US | disclosed |
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137288-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA2 | PARP1 4290/4885GPR119 98/4885HDAC1 571/4885 |
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | CHRNA7, CHRNA5, CHRNA3 | PARP1 3492/4885GPR119 99/4885HDAC1 1254/4885 |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | PARP1 4290/4885GPR119 98/4885HDAC1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.